BioLineRx to Report Second Quarter 2021 Results on August 18, 2021
BioLineRx Ltd. (NASDAQ: BLRX) will announce its unaudited financial results for Q2 2021 on August 18, 2021, before US markets open. A conference call, featuring CEO Philip Serlin, is scheduled for 10:00 a.m. EDT on the same day. Stakeholders can access the call via the Investor Relations page. BioLineRx focuses on oncology, with its lead program Motixafortide (BL-8040) evaluated in multiple studies, including for pancreatic cancer in collaboration with MSD. The company is also developing AGI-134 for solid tumors.
- None.
- None.
TEL AVIV, Israel, Aug. 12, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended June 30, 2021 on Wednesday, August 18, 2021, before the US markets open.
The Company will host a conference call on Wednesday, August 18, 2021 at 10:00 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
To dial into the conference call, please dial +1-866-744-5399 from the U.S. or +972-3-918-0644 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call on the Investor Relations page of BioLineRx's website. A dial-in replay of the call will be available until August 20, 2021; please dial +1-888-295-2634 from the U.S. or +972-3-925-5904 internationally.
About BioLineRx
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.
The Company's lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem-cell mobilization for autologous bone-marrow transplantation. Motixafortide was also successfully evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy under a clinical trial collaboration agreement with MSD (BioLineRx owns all rights to Motixafortide), and is currently being studied in combination with LIBTAYO® and chemotherapy as a first-line PDAC therapy.
BioLineRx is also developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.
For additional information on BioLineRx, please visit the Company's website at www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events.
Contact:
Tim McCarthy
LifeSci Advisors, LLC
+1-212-915-2564
tim@lifesciadvisors.com
or
Moran Meir
LifeSci Advisors, LLC
+972-54-476-4945
moran@lifesciadvisors.com
View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-second-quarter-2021-results-on-august-18-2021-301354370.html
SOURCE BioLineRx Ltd.
FAQ
When will BioLineRx release its Q2 2021 financial results?
What time is the BioLineRx conference call on August 18, 2021?
Who will be speaking at the BioLineRx conference call?
How can I access the BioLineRx conference call?
What is the lead program of BioLineRx?
What are the clinical trials associated with Motixafortide?
What is AGI-134 being developed for by BioLineRx?
